In Brief This Week: PerkinElmer; Sequenom; Lab21; Trovagene; NuGen Technologies | GenomeWeb

NEW YORK (GenomeWeb News) – PerkinElmer this week said that its board of directors has declared a quarterly dividend of $.07 per share payable on Aug. 10, to all shareholders of record at the close of business on July 20.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.